Moleculin Awarded New Rare Pediatric Disease Designation from U.S. FDA for WP1066 for the Treatment of Ependymoma
- Wednesday, April 14, 2021, 6:52
- PR Newswire
- Add a comment
HOUSTON, April 14, 2021 /PRNewswire/ — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced today that the U.S. Food and Drug…
About the Author
admin has written 20543 stories on this site.